Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma

Journal of Neurosurgery

Volumn 122, Issue 5, 2015, Pages 1144-1150

  Sun, Matthew Z ^a   Oh, Taemin ^b   Ivan, Michael E ^a   Clark, Aaron J ^a   Safaee, Michael ^a   Sayegh, Eli T ^b   Kaur, Gurvinder ^b   Parsa, Andrew T ^b   Bloch, Orin ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Glioblastoma; Oncology; Overall survival; Progression free survival; The Cancer Genome Atlas; Treatment delay

Indexed keywords

BEVACIZUMAB; CARMUSTINE; LOMUSTINE; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; GLIOBLASTOMA; GROUPS BY AGE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; THERAPY DELAY; TIME TO TREATMENT; TREATMENT DURATION; TUMOR RECURRENCE; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME-TO-TREATMENT; YOUNG ADULT;

EID: 84936743446     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2014.9.JNS14193     Document Type: Article

References (17)

1. Blumenthal DT, Won M, Mehta MP, Curran WJ, Souhami L, Michalski JM, et al: Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. J Clin Oncol 27:733-739, 2009
2. Burnet NG, Jena R, Jefferies SJ, Stenning SP, Kirkby NF: Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment. Clin Oncol (R Coll Radiol) 18:93-103, 2006
3. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
4. Do V, Gebski V, Barton MB: The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother Oncol 57:131-136, 2000
5. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al: Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29-38, 2008
6. Graus F, Bruna J, Pardo J, Escudero D, Vilas D, Barceló I, et al: Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. Neuro Oncol 15:797-805, 2013
7. Irwin C, Hunn M, Purdie G, Hamilton D: Delay in radiotherapy shortens survival in patients with high grade glioma. J Neurooncol 85:339-343, 2007
8. Kirkby NF, Jefferies SJ, Jena R, Burnet NG: A mathematical model of the treatment and survival of patients with highgrade brain tumours. J Theor Biol 245:112-124, 2007
9. Lai R, Hershman DL, Doan T, Neugut AI: The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme. Neuro Oncol 12:190-198, 2010
10. Lawrence YR, Blumenthal DT, Matceyevsky D, Kanner AA, Bokstein F, Corn BW: Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line? J Neurooncol 105:1-7, 2011
11. Noel G, Huchet A, Feuvret L, Maire JP, Verrelle P, Le Rhun E, et al: Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy. J Neurooncol 109:167-175, 2012
12. Noël G, Quetin P, Heymann S, Karamanoukian D, Schott R: [Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma.] Cancer Radiother 13:17-23, 2009 (Fr)
13. Patel VN, Gokulrangan G, Chowdhury SA, Chen Y, Sloan AE, Koyutürk M, et al: Network signatures of survival in glioblastoma multiforme. PLOS Comput Biol 9:e1003237, 2013
14. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466, 2009
15. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
16. Valduvieco I, Verger E, Bruna J, Caral L, Pujol T, Ribalta T, et al: Impact of radiotherapy delay on survival in glioblastoma. Clin Transl Oncol 15:278-282, 2013
17. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010